USA flag logo/image

An Official Website of the United States Government

USE OF ANTIBODIES TO MODIFIED ALPHA 1 ANTICHYMOTRYPSIN

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
16261
Program Year/Program:
1991 / SBIR
Agency Tracking Number:
16261
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Athens Research And Technology
P O Box 5494 Athens, GA 30604
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1991
Title: USE OF ANTIBODIES TO MODIFIED ALPHA 1 ANTICHYMOTRYPSIN
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

ALZHEIMER'S DISEASE (AD), A LEADING HEALTH PROBLEM FOR THIS COUNTRY, AFFECTS 5 TO L0 PERCENT OF THOSE OVER 65. BY THE YEAR 2000, THIS AGING POPULATION WILL DOUBLE. A TEST PERMITTING A DEFINITIVE AND EARLY DIAGNOSIS OF AD IS GREATLY NEEDED. WE SEEK TO DEVELOP SUCH A DIAGNOSTIC TEST USING MABS IT HAS RAISED TO A MODIFIED FORM OF ALX. IN PHASE I STUDY, ART WILL CHARACTERIZE ITS MABS, DESIGN A PILOT IMMUNOASSAY, AND EVALUATE THE ASSAY'S DIAGNOSTIC POTENTIAL USING CEREBROSPINAL FLUID (CSF) AND PLASMA SAMPLES FROM NORMAL PERSONS AND PATIENTS WITH AD. IF PHASE I STUDIES ARE SUCCESSFUL, IN PHASE II, THE ASSAY WILL BE DEVELOPED AS A COMMERCIAL TEST. THE AVAILABILITY OF A DIAGNOSTIC TEST FOR AD IS CLEARLY IMPORTANT. EARLY DIAGNOSIS OF AD WOULD LEAD TO BETTER MANAGEMENT OF AD PATIENT CARE. AN ACCURATE DIAGNOSTIC TEST WOULD ASSIST RESEARCHERS DEVELOPING AND EVALUATING AD THERAPIES. FINALLY, IN THE EVENT A THERAPY IS DISCOVERED, THE TEST COULD BE USED TO MONITOR THE EFFICACY OF THE TREATMENT IN AD PATIENTS.

Principal Investigator:

Lloyd, Cynthia A
Principal Investigator
4045460207

Business Contact:

1 r43 ag10076- 01
Small Business Information at Submission:

Athens Research And Technology
P O Box 5494 Athens, GA 30604

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No